Cancer: Screening

Department of Health and Social Care written question – answered on 12th February 2019.

Alert me about debates like this

Photo of Lord Warner Lord Warner Crossbench

To ask Her Majesty's Government what assessment they have made of the implications for patient access to treatment for those continuing to rely on the National Tariff Payment System to fund cancer genomic tests under the Genomic Medicine Service in England.

Photo of Baroness Blackwood of North Oxford Baroness Blackwood of North Oxford The Parliamentary Under-Secretary for Health and Social Care

Funding for cancer genomic testing is included under the National Tariff Payment System, excluding whole genome sequencing which NHS England is funding nationally, and is included within the healthcare resource group tariff payment for an individual patient. For example, epidermal growth factor receptor (EGFR) testing for lung cancer, along with oestrogen (positive/negative progesterone) receptor status and human epidermal growth factor receptor 2 (HER2) testing for breast cancer have been established tests within the National Health Service for a number of years.

Cancer genomic testing will continue to be funded by the National Tariff Payment System and the National Genomic Test Directory outlines the cancer genomic tests which will be delivered by the NHS in England.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.